Format

Send to

Choose Destination
J Endocrinol Invest. 2018 Jul 10. doi: 10.1007/s40618-018-0922-0. [Epub ahead of print]

DNA methylation alterations as therapeutic prospects in thyroid cancer.

Zhang K1,2, Li C1,2,3, Liu J1,2, Tang X1,2,4, Li Z5,6.

Author information

1
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
2
Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Xiangya Road #110, Changsha, 410078, Hunan, People's Republic of China.
3
Department of Pharmacy, ZhuZhou Central Hospital, ZhuZhou, 410078, People's Republic of China.
4
Department of Center for ADR monitoring of Hubei, Wuhan, 430071, People's Republic of China.
5
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. lizhi489@163.com.
6
Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Xiangya Road #110, Changsha, 410078, Hunan, People's Republic of China. lizhi489@163.com.

Abstract

BACKGROUND:

Thyroid cancer is one of the most common endocrine malignancies. Although the 10-year survival rate of differentiated thyroid cancer (DTC) is about 90% after conventional treatments, a small proportion of patients still suffer from tumor recurrence or drug resistance.

OBJECTIVE:

This review article summarizes recent researches and clinical trials related to target drugs that reduce mortality in thyroid cancer.

METHODS:

This is a review of the recent literature and clinical trials on the three main aspects including methylation genes in thyroid cancers, the relationship between BRAF mutation and gene methylation, target and dehypermethylation drugs in clinical trials.

RESULTS:

We propose new approaches to treating malignant thyroid cancer, based on advances in understanding the relationship between genetic and epigenetic changes in thyroid cancer. Although the effect of traditional treatment for thyroid cancer is relatively good, a small proportion of patients still suffer from tumor recurrence or drug resistance. Molecular targeted drugs and dehypermethylation drugs have more promising outcomes in aggressive thyroid cancer compared with conventional treatments.

CONCLUSION:

Based on what was discussed in this review, we suggest that integration of epigenetic and targeted therapies into conventional treatments will reduce the occurrence of refractory radioiodine differentiated thyroid cancer and improve the outcomes in aggressive thyroid cancer patients.

KEYWORDS:

BRAF mutation; DNA methylation; Personalized therapy; Thyroid cancer

PMID:
29992502
DOI:
10.1007/s40618-018-0922-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center